Immune System Key (ISK) is engaged in the discovery and development of treatments for malignant cancers and autoimmune diseases, with a primary focus on treating patients with acute myeloid leukemia (AML), pancreatic cancer, and triple-negative breast cancer. Its assets are based on novel human-secreted peptides that were discovered by the company's founders. ISK's lead compound is Nerofe, which offers the potential to inhibit all three biological processes that support cancer progression. In phase-1 testing, researchers demonstrated induction of a strong anti-angiogenic effect and activation of anticancer immune response. In addition, in-vitro experiments indicate that Nerofe may have a strong inhibitory effect on cancer cell proliferation. Nerofe was granted orphan status by the FDA for the treatment of AML. The company has also developed a novel marker whose presence in a patient's biopsy can help predict the success of treatment with Nerofe.